A Phase 1 interventional study of VHX-896 and iloperidone and Iloperidone and VHX-896 in Healthy, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-11.
Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment
This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers
Vanda Pharmaceuticals is the lead sponsor of 81 studies on the registry; 18 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 22 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: VHX-896 and iloperidone
Drug: Iloperidone and VHX-896
oral tablet
oral tablet
Bioequivalence between VHX-896 tablets relative to iloperidone tablets
as measured by plasma concentrations
Time frame: 96 hours
Assessment of Safety and Tolerability of a single dose of VHX-896
As measured by the incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs
Time frame: 17 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanda Pharmaceuticals